Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD1 | O95696 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161644 | 0.83 | TSHR (0.51) | PTGS2LMNAPTGS1ALDH1A1HSD17B10 | |
| SCHEMBL733946 | 0.83 | TSHR (0.51) | PTGS2LMNAPTGS1ALDH1A1HSD17B10 | |
| SCHEMBL4126980 | 0.83 | POLB (0.48) | BRD1BRPF1PTGS2TDP1LMNA | |
| SCHEMBL3757908 | 0.81 | PTGS2 (0.54) | BRD1BRPF1PTGS2ALDH3A1 | |
| SCHEMBL994541 | 0.80 | TDP1 (0.61) | PTGS2TDP1LMNAALDH1A1HSD17B10 | |
| SCHEMBL68413 | 0.80 | KMT2A (0.48) | PTGS2TDP1PTGS1ALDH3A1CA12 | |
| SCHEMBL5565043 | 0.80 | KMT2A (0.40) | PTGS2LMNAALDH1A1 | |
| SCHEMBL3163675 | 0.79 | HDAC1 (0.43) | BRD1BRPF1PTGS2TDP1LMNA | |
| SCHEMBL2011324 | 0.79 | CA2 (0.62) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL29407092 | 0.79 | CA2 (0.62) | PTGS2PTGS1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| WO-2026104681-A1 | NEW SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260001886-A1 | ENPP1 INHIBITORS I | RE VENTURES I LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260001864-A1 | COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | NANJING SHUOHUI PHARMATECHNOLOGY CO., LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC (KR) | 2025-12-04 | — | — | US | disclosed |
| WO-2025233863-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-08-19 | — | — | US | disclosed |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | VANDERBILT UNIVERSITY | 2025-08-07 | — | — | US | disclosed |
| WO-2025124698-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-19 | — | — | WO | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-5627285-A | HYPOTENSIVE AGENTS AND TREATMENT OF ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-06 | — | — | US | disclosed |
| US-5475016-A | Hypotensive, anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| US-5364942-A | Treatment of hypertension and atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1994-11-15 | — | — | US | disclosed |
| US-5318980-A | Antihypertensive and antiatherosclerotic agents | BAYER AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | disclosed |
| CN-1078468-A | The pyridone that Sulphonylbenzyl replaces | BAYER AG (DE) | 1993-11-17 | — | — | CN | disclosed |
| CN-1077710-A | The imidazoles that Sulphonylbenzyl replaces | BAYED AG (DE) | 1993-10-27 | — | — | CN | disclosed |
| US-5254543-A | Hypotensive, anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-19 | — | — | US | disclosed |
| CN-1077195-A | The imidazopyridine that has replaced Sulphonylbenzyl | BAYER AG (DE) | 1993-10-13 | — | — | CN | disclosed |
| US-4507315-A | Hypoglycaemic and hypolipidaemic benzamide substituted (1H-) imidazole derivatives and compositions | MAY & BAKER LIMITED (GB) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367173-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP1, ENPP3, SMPD1 | BRD1 3072/4885BRPF1 1088/4885PTGS2 1002/4885 |
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | BRD1 1114/4885BRPF1 2622/4885PTGS2 1092/4885 |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | PLD1, PLD2, NAPEPLD | BRD1 75/4885BRPF1 469/4885PTGS2 1334/4885 |
| US-20260001886-A1 | ENPP1 INHIBITORS I | ENPP1, ENPP2, ENPP3 | BRD1 1583/4885BRPF1 1629/4885PTGS2 2203/4885 |
| US-20260001864-A1 | COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | SLC10A2, SLC6A11, ABCB11 | BRD1 1497/4885BRPF1 1053/4885PTGS2 363/4885 |
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | BRD1 3709/4885BRPF1 2954/4885PTGS2 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.